Ofatumumab

🧮 Dose calculator

Multiple sclerosis (relapsing) · Regimen source: FDA Kesimpta · 2.2

• • Screen HBV, immunoglobulins and liver tests before starting. FDA Kesimpta · 2.1

Enter age (weight is optional for this regimen).

👥 Special populations

• 🤰 PregnancyUse with caution

  Label states no clear risk or has limited data; use only if needed, under medical advice. FDA Kesimpta · 8.1

  “Risk Summary There are no adequate data on the developmental risk associated with the use of KESIMPTA in pregnant women.”

• 🤱 BreastfeedingUse with caution

  Label: use with caution while breastfeeding; see the label text. FDA Kesimpta · 8.2

  “Risk Summary There are no data on the presence of ofatumumab in human milk, the effects on the breastfed infant, or the effects of the drug on milk production.”

• 👶 ChildrenSafety not established

  Label: safety and effectiveness in children have not been established. FDA Kesimpta · 8.4

  “Safety and effectiveness in pediatric patients have not been established.”

• 👴 Older adultsUse with caution

  Label: use with caution in older adults, usually starting at the low end of the dose range. FDA Kesimpta · 8.5

  “Clinical studies of KESIMPTA did not include sufficient numbers of geriatric patients to determine whether they respond differently from younger subjects.”

• ⚥ Females & males of reproductive potentialUse with caution

  Label has advice on pregnancy testing, contraception or fertility for females and males. FDA Kesimpta · 8.3

  “Contraception Females of childbearing potential should use effective contraception while receiving KESIMPTA and for 6 months after the last treatment of KESIMPTA.”